ABHD17B

Summary

ABHD17B (abhydrolase domain containing 17B, depalmitoylase, HGNC:24278) is a protein-coding gene on chromosome 9q21.13, encoding Alpha/beta hydrolase domain-containing protein 17B (Q5VST6). Hydrolyzes fatty acids from S-acylated cysteine residues in proteins.

Enables palmitoyl-(protein) hydrolase activity. Involved in protein depalmitoylation. Located in membrane.

Source: NCBI Gene 51104 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 45 total — 7 pathogenic, 4 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_001025780

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24278
Approved symbol	ABHD17B
Name	abhydrolase domain containing 17B, depalmitoylase
Location	9q21.13
Locus type	gene with protein product
Status	Approved
Aliases	CGI-67
Ensembl gene	ENSG00000107362
Ensembl biotype	protein_coding
OMIM	617943
Entrez	51104

Gene structure

Transcript identifiers

Ensembl transcripts: 25 — 25 protein_coding

ENST00000333421, ENST00000377041, ENST00000860588, ENST00000860589, ENST00000860590, ENST00000860591, ENST00000860592, ENST00000860593, ENST00000860594, ENST00000860595, ENST00000860596, ENST00000860597, ENST00000860598, ENST00000860599, ENST00000860600, ENST00000930684, ENST00000930685, ENST00000930686, ENST00000930687, ENST00000930688, ENST00000945709, ENST00000945710, ENST00000945711, ENST00000945712, ENST00000945713

RefSeq mRNA: 2 — MANE Select: NM_001025780 NM_001025780, NM_016014

CCDS: CCDS35042, CCDS35043

Canonical transcript exons

ENST00000333421 — 4 exons

Exon	Start	End
ENSE00001161970	71870083	71870262
ENSE00001308379	71865152	71867006
ENSE00001327650	71874614	71875083
ENSE00001821356	71910634	71911193

Expression profiles

Bgee: expression breadth ubiquitous, 264 present calls, max score 98.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.0211 / max 138.8663, expressed in 1774 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
100935	11.3008	1763
100934	0.9719	619
100933	0.7484	412

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	98.48	gold quality
secondary oocyte	CL:0000655	98.26	gold quality
epithelium of nasopharynx	UBERON:0001951	96.52	gold quality
Brodmann (1909) area 23	UBERON:0013554	96.51	gold quality
amniotic fluid	UBERON:0000173	95.35	gold quality
mucosa of paranasal sinus	UBERON:0005030	95.29	gold quality
bronchial epithelial cell	CL:0002328	95.24	gold quality
gingival epithelium	UBERON:0001949	95.03	gold quality
oocyte	CL:0000023	94.98	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.81	gold quality
buccal mucosa cell	CL:0002336	94.72	gold quality
jejunal mucosa	UBERON:0000399	94.56	gold quality
esophagus squamous epithelium	UBERON:0006920	94.44	gold quality
inferior vagus X ganglion	UBERON:0005363	94.36	gold quality
gingiva	UBERON:0001828	93.71	gold quality
palpebral conjunctiva	UBERON:0001812	93.49	gold quality
colonic mucosa	UBERON:0000317	93.08	gold quality
oral cavity	UBERON:0000167	92.53	gold quality
subthalamic nucleus	UBERON:0001906	92.41	gold quality
visceral pleura	UBERON:0002401	92.36	gold quality
postcentral gyrus	UBERON:0002581	91.99	gold quality
entorhinal cortex	UBERON:0002728	91.96	gold quality
corpus callosum	UBERON:0002336	91.91	gold quality
parietal pleura	UBERON:0002400	91.88	gold quality
substantia nigra pars reticulata	UBERON:0001966	91.75	gold quality
ventral tegmental area	UBERON:0002691	91.68	gold quality
parietal lobe	UBERON:0001872	91.38	gold quality
globus pallidus	UBERON:0001875	91.35	gold quality
medial globus pallidus	UBERON:0002477	90.98	gold quality
germinal epithelium of ovary	UBERON:0001304	90.94	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting ABHD17B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-1276	99.36	68.18	1642
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-1253	99.12	67.08	1688
HSA-MIR-583	98.71	67.44	1791
HSA-MIR-5192	96.89	63.35	879

Literature-anchored findings (GeneRIF, showing 1)

• ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. (PMID:33927411)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	abhd17b	ENSDARG00000035571
mus_musculus	Abhd17b	ENSMUSG00000047368
rattus_norvegicus	Abhd17b	ENSRNOG00000012514
caenorhabditis_elegans		WBGENE00008497
caenorhabditis_elegans		WBGENE00008498

Paralogs (7): ABHD12 (ENSG00000100997), ABHD17A (ENSG00000129968), ABHD12B (ENSG00000131969), ABHD17C (ENSG00000136379), ABHD13 (ENSG00000139826), ABHD16B (ENSG00000183260), ABHD16A (ENSG00000204427)

Protein

Protein identifiers

Alpha/beta hydrolase domain-containing protein 17B — Q5VST6 (reviewed: Q5VST6)

All UniProt accessions (2): Q5VST6, A0A384MEH9

UniProt curated annotations — full annotation on UniProt →

Function. Hydrolyzes fatty acids from S-acylated cysteine residues in proteins. Has depalmitoylating activity towards DLG4/PSD95. Has depalmitoylating activity towards GAP43. Has depalmitoylating activity towards MAP6. Has depalmitoylating activity towards NRAS.

Subcellular location. Cell membrane. Recycling endosome membrane. Cell projection. Dendritic spine. Postsynaptic density membrane.

Post-translational modifications. Palmitoylated on cysteine residues located in a cysteine cluster at the N-terminus which promotes membrane localization. Palmitoylation is required for post-synaptic localization and for depalmitoylating activity towards DLG4/PSD95.

Activity regulation. Inhibited by palmostatin-B.

Similarity. Belongs to the AB hydrolase superfamily. ABHD17 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5VST6-1	1	yes
Q5VST6-2	2

RefSeq proteins (2): NP_001020951, NP_057098 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR022742	ABHD17C-like	Domain
IPR029058	AB_hydrolase_fold	Homologous_superfamily

Pfam: PF12146

Catalyzed reactions (Rhea), 1 shown:

• S-hexadecanoyl-L-cysteinyl-[protein] + H2O = L-cysteinyl-[protein] + hexadecanoate + H(+) (RHEA:19233)

UniProt features (11 total): active site 3, sequence conflict 3, sequence variant 2, chain 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VST6-F1	92.51	0.84

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 170 (charge relay system); 235 (charge relay system); 264 (charge relay system)

Post-translational modifications (1): 282

Function

Pathways and Gene Ontology

Reactome pathways

5 pathways

ID	Pathway
R-HSA-9648002	RAS processing
R-HSA-162582	Signal Transduction
R-HSA-5673001	RAF/MAP kinase cascade
R-HSA-5683057	MAPK family signaling cascades
R-HSA-5684996	MAPK1/MAPK3 signaling

MSigDB gene sets: 223 (showing top): RNGTGGGC_UNKNOWN, AP1_01, GOBP_PROTEIN_LOCALIZATION_TO_CYTOSKELETON, YAATNRNNNYNATT_UNKNOWN, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, NKX25_02, GOBP_MACROMOLECULE_DEACYLATION, GOBP_POSITIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_CELLULAR_COMPONENT_MAINTENANCE, TGACCTY_ERR1_Q2, GTACAGG_MIR486, USF_C, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_LOCALIZATION, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION

GO Biological Process (7): protein depalmitoylation (GO:0002084), regulation of postsynapse organization (GO:0099175), regulation of protein localization to synapse (GO:1902473), negative regulation of protein localization to microtubule (GO:1902817), regulation of dendritic spine maintenance (GO:1902950), positive regulation of protein localization to endosome (GO:1905668), macromolecule depalmitoylation (GO:0098734)

GO Molecular Function (2): palmitoyl-(protein) hydrolase activity (GO:0008474), hydrolase activity (GO:0016787)

GO Cellular Component (13): plasma membrane (GO:0005886), endosome membrane (GO:0010008), membrane (GO:0016020), dendritic spine (GO:0043197), recycling endosome membrane (GO:0055038), postsynaptic density membrane (GO:0098839), postsynaptic recycling endosome membrane (GO:0098944), glutamatergic synapse (GO:0098978), endosome (GO:0005768), postsynaptic density (GO:0014069), cell projection (GO:0042995), synapse (GO:0045202), postsynaptic membrane (GO:0045211)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
RAF/MAP kinase cascade	1
MAPK1/MAPK3 signaling	1
Signal Transduction	1
MAPK family signaling cascades	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
postsynapse	2
protein deacylation	1
lipoprotein catabolic process	1
macromolecule depalmitoylation	1
regulation of synapse organization	1
postsynapse organization	1
regulation of protein localization	1
protein localization to synapse	1
protein localization to microtubule	1
regulation of protein localization to microtubule	1
negative regulation of protein localization	1
dendritic spine maintenance	1
regulation of postsynapse organization	1
regulation of plasma membrane bounded cell projection organization	1
protein localization to endosome	1
positive regulation of protein localization	1
regulation of protein localization to endosome	1
macromolecule deacylation	1
thiolester hydrolase activity	1
palmitoyl hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
membrane	1
cell periphery	1
endosome	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
dendrite	1
neuron spine	1
endosome membrane	1
recycling endosome	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1
postsynaptic recycling endosome	1
postsynaptic endosome membrane	1
synapse	1
endomembrane system	1
cytoplasmic vesicle	1

Protein interactions and networks

STRING

616 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ABHD17B	ABHD10	Q9NUJ1	589
ABHD17B	C9orf57	Q5W0N0	577
ABHD17B	RBBP9	O75884	541
ABHD17B	LYPLA1	O75608	500
ABHD17B	LYPLA2	O95372	500
ABHD17B	AFMID	Q63HM1	497
ABHD17B	PPME1	Q9Y570	493
ABHD17B	LYPLAL1	Q5VWZ2	483
ABHD17B	ABHD6	Q9BV23	480
ABHD17B	ABHD11	Q8NFV4	463
ABHD17B	ABHD16A	O95870	459
ABHD17B	PPT2	Q9UMR5	449
ABHD17B	PPT1	P50897	449
ABHD17B	PAFAH1B2	P68402	447
ABHD17B	ACOT4	Q8N9L9	446

IntAct

68 interactions, top by confidence:

A	B	Type	Score
DYNLT2B	DYNLT1	psi-mi:“MI:0914”(association)	0.790
TRIM16L	CCDC22	psi-mi:“MI:0914”(association)	0.640
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
TOR1AIP2	TMEM223	psi-mi:“MI:0914”(association)	0.530
CXCR4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
MAS1	POTEF	psi-mi:“MI:0914”(association)	0.530
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
SLC2A12	METTL15	psi-mi:“MI:0914”(association)	0.530
DEFA1	MANBA	psi-mi:“MI:0914”(association)	0.530
NRBP1	TBC1D4	psi-mi:“MI:0914”(association)	0.530
DYNLT2B	SNX2	psi-mi:“MI:0914”(association)	0.530
MFSD4A	HIP1R	psi-mi:“MI:0914”(association)	0.530
PRG3	ZNF324	psi-mi:“MI:0914”(association)	0.530
SFTA2	TBCE	psi-mi:“MI:0914”(association)	0.530
APLNR	SLC33A1	psi-mi:“MI:0914”(association)	0.530
GPR17	IPO8	psi-mi:“MI:0914”(association)	0.530
Npc1	ESYT2	psi-mi:“MI:0914”(association)	0.350
AVPR2	GXYLT2	psi-mi:“MI:0914”(association)	0.350
GPR17	TMEM120B	psi-mi:“MI:0914”(association)	0.350
CD80	POTEF	psi-mi:“MI:0914”(association)	0.350
A4GALT	VPS37C	psi-mi:“MI:0914”(association)	0.350
C5AR1	TCAF2	psi-mi:“MI:0914”(association)	0.350
GPR182	METTL15	psi-mi:“MI:0914”(association)	0.350
OPRL1	METTL15	psi-mi:“MI:0914”(association)	0.350
CRLF2	METTL15	psi-mi:“MI:0914”(association)	0.350
GLMP	RTL8C	psi-mi:“MI:0914”(association)	0.350
SLC22A4	RTL8C	psi-mi:“MI:0914”(association)	0.350
AQP3	RTL8C	psi-mi:“MI:0914”(association)	0.350
CMTM8	UBXN8	psi-mi:“MI:0914”(association)	0.350

BioGRID (81): ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS), ABHD17B (Affinity Capture-MS)

ESM2 similar proteins: A1Z6E0, A2BHJ4, A8IU92, B0X9V1, B3MDR0, B3NRP1, B4F739, B4GBN7, B4HQ29, B4J6Q0, B4KNC5, B4LMQ3, B4MR59, B4P4K8, B4QE02, P00860, P0C2W1, P0CH38, P11926, P27117, P27119, P27120, P48455, P53041, P53042, Q0G819, Q16XV7, Q290L5, Q5BJ41, Q5E9X6, Q5VST6, Q5XH73, Q60676, Q68FK8, Q6AXU9, Q6AY17, Q6IR85, Q6NZ03, Q7M759, Q7QGL9

Diamond homologs: A0A2S3R7M0, A5PKD9, B5DFK7, Q2HJ19, Q5UQK4, Q5VST6, Q5XIJ5, Q5ZJ01, Q5ZJX1, Q6AY17, Q6DCC5, Q6DD70, Q6DEY3, Q6GL10, Q6IRP4, Q6PCB6, Q7M759, Q7ZVZ7, Q8RXP6, Q8VCV1, Q96GS6, Q99JW1, Q9KS12, P77538, P9WLC6, P9WLC7, Q21221, Q8XA81, P54069, Q08C93, Q32LS6, Q7Z5M8, Q8Z4M8, Q8ZN39, B4F753, Q08DW9, Q4R766, Q5ZIN0, Q6AYT7, Q8N2K0

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 111 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SLC-mediated transmembrane transport	9	7.1×	7e-04
Peptide ligand-binding receptors	7	6.9×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
G protein-coupled receptor signaling pathway	15	5.5×	6e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

45 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	7
Likely pathogenic	4
Uncertain significance	28
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (11)

Variant ID	HGVS	Classification
148901	GRCh38/hg38 9q21.11-21.32(chr9:68499530-83670227)x1	Pathogenic
1527488	GRCh37/hg19 9p24.3-q21.32(chr9:203861-84155399)	Pathogenic
153561	GRCh38/hg38 9p24.3-q22.1(chr9:203861-88130444)x4	Pathogenic
154945	GRCh38/hg38 9p24.3-q21.31(chr9:193412-79877816)x3	Pathogenic
441750	GRCh37/hg19 9q21.11-22.1(chr9:70966262-90761254)x4	Pathogenic
442687	GRCh37/hg19 9q21.11-21.31(chr9:68734571-83557267)x3	Pathogenic
563680	GRCh37/hg19 9q21.11-21.32(chr9:68999534-84656998)x1	Pathogenic
155686	GRCh38/hg38 9q21.11-21.13(chr9:68624483-72028837)x3	Likely pathogenic
443719	GRCh37/hg19 9q21.11-21.13(chr9:71079379-75905808)x1	Likely pathogenic
4796343	GRCh38/hg38 9p24.3-q21.13(chr9:208455-72054336)x3	Likely pathogenic
617751	Single allele	Likely pathogenic

SpliceAI

1116 predictions. Top by Δscore:

Variant	Effect	Δscore
9:71867005:TG:T	acceptor_gain	1.0000
9:71867007:C:CC	acceptor_gain	1.0000
9:71870081:A:AC	donor_gain	1.0000
9:71870082:C:CC	donor_gain	1.0000
9:71870277:CGT:C	acceptor_gain	1.0000
9:71870278:G:C	acceptor_gain	1.0000
9:71870279:T:C	acceptor_gain	1.0000
9:71870279:T:TC	acceptor_gain	1.0000
9:71876436:T:C	acceptor_gain	1.0000
9:71866803:T:TA	donor_gain	0.9900
9:71866816:A:AC	donor_gain	0.9900
9:71866817:C:CC	donor_gain	0.9900
9:71866837:A:AC	donor_gain	0.9900
9:71866838:C:CC	donor_gain	0.9900
9:71866841:T:A	donor_gain	0.9900
9:71866875:TCA:T	donor_gain	0.9900
9:71867002:CAATG:C	acceptor_gain	0.9900
9:71867003:AATG:A	acceptor_gain	0.9900
9:71867004:ATG:A	acceptor_gain	0.9900
9:71867004:ATGC:A	acceptor_loss	0.9900
9:71867005:TGC:T	acceptor_loss	0.9900
9:71867006:GCTG:G	acceptor_loss	0.9900
9:71867007:C:G	acceptor_loss	0.9900
9:71867008:T:G	acceptor_loss	0.9900
9:71870075:CTACT:C	donor_loss	0.9900
9:71870076:TACTT:T	donor_loss	0.9900
9:71870077:ACTTA:A	donor_loss	0.9900
9:71870078:CTTAC:C	donor_loss	0.9900
9:71870079:TTACT:T	donor_loss	0.9900
9:71870080:TA:T	donor_loss	0.9900

AlphaMissense

1877 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:71866848:A:G	L269P	1.000
9:71866852:C:T	E268K	1.000
9:71866857:T:A	D266V	1.000
9:71866857:T:G	D266A	1.000
9:71866858:C:G	D266H	1.000
9:71866859:A:C	N265K	1.000
9:71866859:A:T	N265K	1.000
9:71866862:G:C	H264Q	1.000
9:71866862:G:T	H264Q	1.000
9:71866863:T:A	H264L	1.000
9:71866863:T:C	H264R	1.000
9:71866864:G:A	H264Y	1.000
9:71866864:G:C	H264D	1.000
9:71866864:G:T	H264N	1.000
9:71866878:A:T	V259D	1.000
9:71866882:A:G	W258R	1.000
9:71866882:A:T	W258R	1.000
9:71866884:A:G	L257P	1.000
9:71866926:C:T	G243D	1.000
9:71866927:C:G	G243R	1.000
9:71866941:A:T	I238N	1.000
9:71866949:A:C	D235E	1.000
9:71866949:A:T	D235E	1.000
9:71866950:T:A	D235V	1.000
9:71866950:T:C	D235G	1.000
9:71866950:T:G	D235A	1.000
9:71866951:C:A	D235Y	1.000
9:71866951:C:G	D235H	1.000
9:71866951:C:T	D235N	1.000
9:71866959:C:A	G232V	1.000

dbSNP variants (sampled 300 via entrez): RS1000038299 (9:71899802 T>C), RS1000112537 (9:71902211 G>A), RS1000209857 (9:71862381 C>T), RS1000231577 (9:71882056 A>G), RS1000261055 (9:71905285 G>A), RS1000282953 (9:71868181 T>C), RS1000343704 (9:71861976 G>A), RS1000345783 (9:71887732 C>G), RS1000453352 (9:71886140 T>C), RS1000547706 (9:71880741 T>C), RS1000588238 (9:71885703 A>T), RS1000590999 (9:71862705 A>C,G,T), RS1000642008 (9:71863031 A>G), RS1000652788 (9:71904573 T>A), RS1000673458 (9:71875662 T>C)

Disease associations

OMIM: gene MIM:617943 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): congenital heart disease (MONDO:0005453), glioma (MONDO:0021042)

Orphanet (1): Glial tumor (Orphanet:182067)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D005910	Glioma	C04.557.465.625.600.380; C04.557.470.670.380; C04.557.580.625.600.380
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2189132 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

31 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, decreases methylation	5
trichostatin A	decreases expression, affects expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Tobacco Smoke Pollution	increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
sodium arsenite	decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Sunitinib	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Coal	decreases expression, increases abundance	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Formaldehyde	decreases expression	1
Smoke	decreases expression, increases abundance	1
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	1
Thimerosal	increases expression	1
Urethane	increases expression	1
Cyclosporine	decreases expression	1
Aflatoxin B1	decreases methylation	1
Antirheumatic Agents	increases expression	1
Okadaic Acid	increases expression	1
Copper Sulfate	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2209093	Binding	Inhibition of FAM108B1 binding to FP-biotin in [12C][14N]-lysine, arginine and [13C6][15N2]-lysine, arginine labeled HEK293T cells at 20 uM after 1 hr by isotopic activity-based protein profiling-MudPIT assay	Discovery and optimization of sulfonyl acrylonitriles as selective, covalent inhibitors of protein phosphatase methylesterase-1. — J Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function
NCT01827059	PHASE2	UNKNOWN	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE